KOD - Kodiak Sciences Inc.
Kodiak Sciences Inc. (NASDAQ: KOD - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eight analysts that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have issued a buy recommendation on the company.
Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into earnings season.
First scientific presentation of Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted in wet age-related macular degeneration scheduled for AAO 2026. Additional presentations include Phase 3 GLOW2 data for Zenkuda in diabetic retinopathy and Phase 1b APEX data for KSI-101 in macular edema secondary to inflammation (MESI).
Kodiak Sciences NASDAQ: KOD reported that its Phase III DAYBREAK study met primary endpoints for two investigational treatments in treatment-naïve patients with wet age-related macular degeneration, or wet AMD, with both therapies demonstrating statistical equivalence to aflibercept on visual-acuity outcomes.
Kodiak Sciences Inc. (NASDAQ: KOD - Get Free Report) Director Bros. Advisors Lp Baker purchased 33,726 shares of the stock in a transaction dated Tuesday, September 29th. The stock was purchased at an average price of $85.05 per share, with a total value of $2,868,396.30. Following the completion of the acquisition, the director directly owned 20,191,214
Kodiak Sciences tripled in a single session after its eye drug cleared a pivotal trial, but a cash-burning biotech with no revenue and a likely share offering complicates any case for chasing the move.
Kodiak surges 178% as positive phase III DAYBREAK data show Zenkuda and tabirafusp-ted met key endpoints against Eylea.
What happened Kodiak Sciences Inc. (NASDAQ: KOD) cleared a pivotal hurdle for Zenkuda. The eye drug matched aflibercept on vision at one year in the Phase 3 DAYBREAK study. Both Zenkuda and tabirafusp-ted met their primary vision endpoints in wet age-related macular degeneration, an eye disease that can cause severe vision loss. Zenkuda also kept
Zenkuda and KSI-501 achieved their primary goals in a Phase 3 study. The global market for retinal drugs could exceed $32 billion by the end of the decade.
Kodiak Sciences Inc. (KOD) Discusses DAYBREAK Topline Data and Primary Endpoint Results Transcript
Kodiak Sciences Inc (NASDAQ:KOD) surged after Zenkuda and tabirafusp-ted met their primary endpoints in the phase III DAYBREAK trial for wet age-related macular degeneration. Shares gained over 162% by midday Monday following the announcement.
Kodiak Sciences (KOD) is experiencing a significant surge in its stock price following the announcement that its lead candidates, Zenkuda and tabirafusp-ted, su
Kodiak Sciences Inc. (NASDAQ:KOD) on Monday released data from the Phase 3 DAYBREAK trial for patients suffering from wet age-related macular degeneration (wAMD).
Shares of Kodiak Sciences Inc. (NASDAQ: KOD - Get Free Report) reached a new 52-week high during trading on Monday. The company traded as high as $64.57 and last traded at $64.57, with a volume of 4558251 shares. The stock had previously closed at $32.35. Wall Street Analyst Weigh In A number of analysts have recently
Kodiak Sciences stock skyrocketed Monday on a double win for its potential rivals to Regeneron Pharmaceuticals' blockbuster eye drug, Eylea.
Kodiak Sciences plans to file for regulatory approval of one drug candidate, Zenkuda, following its success in a trial for wet age-related macular degeneration.
Kodiak Sciences to Host Webcast on Monday, September 28 at 8:30 AM Eastern Time PALO ALTO, Calif., Sept. 25, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that the company will report topline results from DAYBREAK, a Phase 3 study evaluating both Zenkuda TM (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer) for the treatment of patients with wet age-related macular degeneration, on Monday, September 28, 2026.
KOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and vaccine pipelines.
Kodiak Sciences Inc. (NASDAQ: KOD - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eight brokerages that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have assigned a buy recommendation to the company.
For small-cap biotech investors, a single date on the calendar can matter more than a quarter's worth of earnings reports. These companies often burn cash for years without product revenue, betting everything on a single clinical trial readout or an FDA decision.